NASDAQ$RIGL

Rigel Pharmaceuticals Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Reported strong commercial demand with the highest number of TAVALISSE and REZLIDHIA bottles sold in a quarter since launch, along with a net loss of $8.2 million.

Rigel Pharmaceuticals reported Q1 2024 financial results, featuring strong commercial demand with record bottle sales for TAVALISSE and REZLIDHIA. Total revenues reached $29.5 million, with a net loss of $8.2 million, or $0.05 per share.

  • Total revenues were $29.5 million, including $21.1 million from TAVALISSE sales and $4.9 million from REZLIDHIA sales.
  • Net loss for the quarter was $8.2 million, or $0.05 per share, improved from a net loss of $13.5 million in the same period last year.
  • Total costs and expenses decreased to $36.5 million, driven by lower research and development costs and consulting fees.
  • Cash, cash equivalents, and short-term investments totaled $49.6 million as of March 31, 2024.

Headline financials

Total Revenue

$29.5M

Previous: $26.1M+13.3%
EPS

-$0.05

Previous: -$0.80+93.8%
TAVALISSE Net Sales

$21.1K

No prior period
REZLIDHIA Net Sales

$4.9K

No prior period
R&D Expense

$6.03K

No prior period
SG&A Expense

$28.4K

No prior period
Stock-Based Comp

$5.13K

No prior period
Interest Income

$593.00

No prior period
Interest Expense

$1.87K

No prior period
Income Tax Benefit

$0.00

No prior period
Capital Expenditures

-$138K

Previous: -$224K+38.4%
Free Cash Flow

-$8.25M

Previous: -$13.8M+40.1%
Net Income

-$8.25M

Previous: -$13.5M+39.1%
Operating Income

-$6.97M

Previous: -$12.7M+45.3%
Gross Profit

$27.5M

Previous: $25.1M+9.6%
Cash & Equivalents

$25.6M

Previous: $40.3M-36.5%
Total Assets

$127M

Previous: $124M+2.4%

Revenue & EPS history

Rigel · Revenue · Quarterly

$29.5M

Q1 2024+13.3%vs Q1 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Rigel · $2M total across 1 segment · Q2 2023

  • Collaboration Revenue
    $2M-82.3%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+0.2%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+2.8%

Avg return

30 days after

38%

25 / 65 earnings

Positive

+46.4%

Q3 2024

Best reaction

-18.7%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.8%-11.8%+2.3%
Q4 2025-10.2%-15.0%-16.6%
Q3 2025-2.6%+10.6%+35.4%
Q1 2025+0.9%+1.9%+17.7%
Q4 2024-8.1%-11.5%-21.9%
Q3 2024+46.4%+80.5%+68.8%
Q2 2024+12.2%+16.0%+52.4%
Q1 2024-18.7%-19.7%-21.3%
Q4 2023+6.1%+6.8%-12.2%
Q3 2023+5.8%-2.4%+35.7%
Q2 2023-6.5%-11.6%-17.4%
Q1 2023-3.4%-0.8%+17.6%
Q4 2022+17.8%+4.6%-17.8%
Q3 2022+5.3%+4.3%+18.6%
Q2 2022+16.5%+25.6%+27.3%
Q1 2022+7.3%-9.8%-32.5%
Q4 2021+21.1%+21.1%+19.1%
Q3 2021-1.7%-8.8%-26.3%
Q2 2021-7.2%-5.2%+3.2%
Q1 2021-5.2%-7.8%+15.7%
Q4 2020-14.3%-14.1%-23.3%
Q3 2020-3.0%+1.5%+14.1%
Q2 2020+3.7%+6.2%-4.5%
Q1 2020-2.2%-2.7%+2.2%
Q4 2019-2.3%+0.5%-27.6%
Q3 2019-1.9%+4.7%-5.1%
Q2 2019+8.1%+1.9%-15.7%
Q1 2019-5.5%-6.7%-14.7%
Q4 2018-0.9%-1.8%+13.7%
Q3 2018+7.2%-2.7%-3.8%
Q2 2018+10.2%+1.1%+16.8%
Q1 2018+5.3%+7.2%-10.0%
Q4 2017+13.5%+14.5%-18.1%
Q3 2017+1.1%+1.6%+2.4%
Q2 2017-1.3%+1.7%+7.6%
Q1 2017-9.9%-9.2%-19.1%
Q4 2016+2.6%+0.8%+14.3%
Q3 2016-3.1%+1.5%-3.5%
Q2 2016+14.3%+22.7%+37.5%
Q1 2016-10.9%
Q4 2015-6.3%
Q3 2015+8.9%
Q2 2015+4.6%
Q1 2015-10.5%
Q4 2014-1.0%
Q3 2014-1.5%
Q2 2014-6.2%
Q1 2014-10.6%
Q4 2013+17.5%
Q3 2013-9.3%
Q2 2013+2.8%
Q1 2013-0.6%
Q4 2012+5.5%
Q3 2012+2.7%
Q2 2012-7.1%
Q1 2012-2.1%
Q4 2009-9.0%
Q4 2011-9.0%
Q3 2010-5.9%
Q3 2011-5.9%
Q2 2010-3.3%
Q4 2010-3.3%
Q2 2011-3.3%
Q1 2011-11.5%
Q1 2010-5.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro